ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT/Jurkat
CBP74003
| I. Background | |
|
抗體依賴的細(xì)胞介導(dǎo)的細(xì)胞毒性作用（ADCC，antibody-dependent cell-mediated cytotoxicity ）是指抗體的 Fab 段結(jié)合病毒感染的細(xì)胞或腫瘤細(xì)胞的抗原表位，其 Fc 段與殺 傷細(xì)胞（NK 細(xì)胞、巨噬細(xì)胞等）表面的 FcR 結(jié)合，介導(dǎo)殺傷細(xì)胞直接殺傷靶細(xì)胞，它是 抗腫瘤的治療性抗體藥物發(fā)生作用的一種作用重要機(jī)制。 傳統(tǒng)用于測(cè)定 ADCC/ADCP 的方法主要依賴于相關(guān)原代免疫細(xì)胞的分離、體外分化， 進(jìn)而測(cè)量靶細(xì)胞的殺傷或吞噬效應(yīng)。這些方法高度依賴供體原代細(xì)胞，價(jià)格昂貴且費(fèi)時(shí)費(fèi) 力，對(duì)原代細(xì)胞的分離分化過(guò)程對(duì)實(shí)驗(yàn)操作的要求非常高，實(shí)驗(yàn)失敗風(fēng)險(xiǎn)較大，由于分離 分化細(xì)胞純度問(wèn)題，還存在檢測(cè)信號(hào)低以及不穩(wěn)定均一的問(wèn)題。另外，原代細(xì)胞具有不可 再生性，每次實(shí)驗(yàn)的細(xì)胞供體來(lái)源可能都不一致，實(shí)驗(yàn)結(jié)果可重復(fù)性較差，可能存在批次 差異。由于以上這些因素的影響，在需要高質(zhì)量控制的藥物開(kāi)發(fā)過(guò)程中，很難建立穩(wěn)定可 靠的檢測(cè)方法。 |
|
| II. Description | |
|
ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT Jurkat 報(bào)告基因藥靶模 型很好的模擬了體內(nèi) ADCC 的信號(hào)轉(zhuǎn)導(dǎo)過(guò)程，原理見(jiàn)下圖所示。
|
|
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | NFAT-Luc-CD16(V158) |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | Antibody-dependent cell-mediated cytotoxicity |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+300μg/ml hygromycin+1μg/ml puromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Immediately upon receipt, store in liquid nitrogen. |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | Peripheral blood |
| Disease: | Acute T cell leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
Figure 2. Recombinant ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT/Jurkat stably expressing CD16a（V158）.
Figure 3. Dose response of CD20 Ab in ADCC Bioassay Effector Cell (High Affinity)-Fcγ-NFAT Jurkat cell（C36）. Dose response of TNFα Abs in ADCC Bioassay Effector Cell V variant(High Affinity)-Fcγ-NFAT Jurkat cell（C36）with Membrane Anchored TNFα Cells(Suspended,C5).
Figure 4. Dose response of TNFα Abs in ADCC Bioassay Effector Cell V variant(High Affinity)-Fcγ-NFAT Jurkat cell（C36）with Membrane Anchored TNFα Cell (Adherent,C12).
